Floatz logo

MIDAZOLAM

HER2 Mutation

BayerSmall moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the HER2 Mutation cohort.

Asset / SponsorPhaseRating
bay2927088
Bayer
Phase 2BB
Zongertinib
MedSIR
Phase 2CCC
FULVESTRANT
MedSIR
Phase 2CCC
Esomeprazole
Bayer
Phase 1CC
DABIGATRAN ETEXILATE
Bayer
Phase 1CC

View all 10 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →